How has been the historical performance of Marksans Pharma?
Marksans Pharma has shown consistent growth in net sales and profitability, with net sales increasing from 1,000.07 Cr in Mar'19 to 2,622.85 Cr in Mar'25, and profit after tax rising from 80.44 Cr to 382.62 Cr during the same period. The company's earnings per share improved significantly from 1.97 to 8.4, reflecting strong operational efficiency and financial health.
Answer:The historical performance of Marksans Pharma shows a consistent growth trend in net sales and profitability over the years.Breakdown:
Marksans Pharma has demonstrated significant growth in net sales, increasing from 1,000.07 Cr in Mar'19 to 2,622.85 Cr in Mar'25. This upward trajectory reflects a steady rise in total operating income, which also grew from 1,000.07 Cr in Mar'19 to 2,622.85 Cr in Mar'25. The company's operating profit, excluding other income, rose from 132.14 Cr in Mar'19 to 532.69 Cr in Mar'25, indicating improved operational efficiency. Profit before tax followed a similar trend, climbing from 104.31 Cr in Mar'19 to 503.97 Cr in Mar'25, while profit after tax increased from 80.44 Cr to 382.62 Cr over the same period. The earnings per share (EPS) also improved significantly, reaching 8.4 in Mar'25 compared to 1.97 in Mar'19. On the balance sheet, total assets grew from 902.03 Cr in Mar'20 to 3,239.63 Cr in Mar'25, with total liabilities increasing correspondingly from 902.03 Cr to 3,239.63 Cr. The company's cash flow from operating activities showed fluctuations but remained positive, with a cash inflow of 206 Cr in Mar'25. Overall, Marksans Pharma's financial performance reflects a robust growth trajectory across various metrics.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
